Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the company’s stock with a ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ.

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...